GLSI Greenwich LifeSciences Inc

Price (delayed)

$17.51

Market cap

$257.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.54

Enterprise value

$248.14M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 2

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a ...

Highlights
The equity has soared by 117% YoY but it fell by 41% QoQ
The quick ratio is down by 23% from the previous quarter and by 17% YoY
The net income has contracted by 15% YoY

Key stats

What are the main financial stats of GLSI

GLSI stock price

How has the Greenwich LifeSciences stock price performed over time
Intraday
-10.11%
1 week
12.03%
1 month
5.04%
1 year
59.47%
YTD
-16.66%
QTD
-25.36%

Financial performance

How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$21.87M
Net income
-$21.68M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 15% YoY
The operating income has declined by 15% year-on-year

Price vs fundamentals

How does GLSI's price correlate with its fundamentals

Growth

What is Greenwich LifeSciences's growth rate over time

Valuation

What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
82.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is down by 8% year-on-year
The equity has soared by 117% YoY but it fell by 41% QoQ
GLSI's P/B is 65% lower than its last 4 quarters average of 264.9 but 11% higher than its 5-year quarterly average of 83.0

Efficiency

How efficient is Greenwich LifeSciences business performance
The ROA has increased by 38% YoY and by 19% QoQ
The return on equity has increased by 15% since the previous quarter and by 9% year-on-year

Dividends

What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLSI.

Financial health

How did Greenwich LifeSciences financials performed over time
GLSI's total assets is 54% greater than its total liabilities
GLSI's total assets has surged by 184% year-on-year but it is down by 16% since the previous quarter
The current ratio has decreased by 23% from the previous quarter and by 17% YoY
The company's debt is 100% lower than its equity
The equity has soared by 117% YoY but it fell by 41% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.